Profile data is unavailable for this security.
About the company
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). It is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.
- Revenue in USD (TTM)10.63bn
- Net income in USD-479.80m
- Incorporated1989
- Employees5.40k
- LocationVertex Pharmaceuticals Inc50 Northern AvenueBOSTON 02210United StatesUSA
- Phone+1 (617) 341-6393
- Websitehttps://www.vrtx.com/
Mergers & acquisitions
| Acquired company | VRTX:NSQ since announced | Transaction value |
|---|---|---|
| Alpine Immune Sciences Inc | 11.35% | 4.95bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Iqvia Holdings Inc | 15.32bn | 1.41bn | 35.88bn | 88.00k | 25.93 | 5.15 | 14.14 | 2.34 | 7.62 | 7.62 | 83.09 | 38.36 | 0.5762 | -- | 4.77 | 176,034.50 | 5.31 | 3.24 | 7.13 | 4.07 | 35.17 | 34.32 | 9.21 | 6.03 | -- | 3.43 | 0.6598 | 0.00 | 3.98 | 7.55 | 24.47 | 43.39 | 7.17 | -- |
| Regeneron Pharmaceuticals Inc | 13.85bn | 4.65bn | 81.81bn | 13.45k | 18.42 | 2.80 | 15.97 | 5.91 | 40.42 | 40.42 | 120.30 | 266.36 | 0.3979 | 0.6523 | 2.37 | 1,029,524.00 | 13.37 | 20.18 | 14.93 | 23.22 | 86.86 | 87.66 | 33.61 | 38.11 | 4.46 | -- | 0.0844 | -- | 7.76 | 14.34 | -8.87 | 10.72 | 19.32 | -- |
| Vertex Pharmaceuticals Incorporated | 10.63bn | -479.80m | 115.98bn | 5.40k | -- | 7.43 | -- | 10.92 | -1.99 | -1.99 | 40.83 | 60.65 | 0.4834 | 1.67 | 6.46 | 1,967,741.00 | -2.18 | 19.92 | -2.64 | 23.64 | 86.12 | 87.67 | -4.52 | 35.85 | 2.20 | -- | 0.0072 | 0.00 | 10.51 | 26.49 | 8.96 | 46.50 | 22.02 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (World Investors)as of 30 Sep 2024 | 26.81m | 10.39% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 22.00m | 8.52% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 14.42m | 5.59% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 11.82m | 4.58% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 9.62m | 3.73% |
| Capital Research & Management Co. (Global Investors)as of 30 Sep 2024 | 9.00m | 3.49% |
| AllianceBernstein LPas of 30 Sep 2024 | 7.37m | 2.86% |
| Geode Capital Management LLCas of 30 Sep 2024 | 5.94m | 2.30% |
| Jennison Associates LLCas of 30 Sep 2024 | 5.55m | 2.15% |
| JPMorgan Investment Management, Inc.as of 30 Sep 2024 | 4.92m | 1.91% |
